Cancer Genetics, Inc. (CGI) is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes. In August 2014, the Company acquired BioServe Biotechnologies (India) Pvt. Ltd.